Literature DB >> 231403

Endogenous prostaglandin synthesis and the control of lymphocyte function.

D R Webb, T J Rogers, I Nowowiejski.   

Abstract

Prostaglandins serve an important regulatory role in immune responses. Much of their activity seems to involve regulating the early stages of lymphocyte or macrophage activation. Besides the capacity of prostaglandins to control lymphocyte activation directly by blocking transformation, at least one type, PGE2 can induce a class of glass-adherent T-cells to produce a suppressive peptide in vitro. The data we have obtained suggest the existence of a feedback loop in which PG production by an activated T-cell serves as the signal that induces a second T-cell to release a suppressor peptide. This peptide can then regulate the ability of the activated T-cell to pass through the cell cycle. Other examples of feedback loops have recently been postulated or shown to exist among immunocompetent cells. It remains to be shown how these various regulatory loops combine to form the integrated network that modulates immunoresponsiveness.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 231403     DOI: 10.1111/j.1749-6632.1979.tb47120.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  4 in total

1.  Immunosuppressive actions of prostaglandins and the possible increase in chronic inflammation after cyclo-oxygenase inhibitors.

Authors:  G P Lewis; M L Barrett
Journal:  Agents Actions       Date:  1986-10

2.  Regulation of human immunoglobulin production in vitro by prostaglandin E2.

Authors:  N D Staite; G S Panayi
Journal:  Clin Exp Immunol       Date:  1982-07       Impact factor: 4.330

3.  The effect of indomethacin on the activation and effector function of suppressor cells from tumor-bearing mice.

Authors:  B L Pope
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

4.  Monocyte factors modulate in vitro T-lymphocyte mitogenesis in protein malnutrition.

Authors:  R C Bell; L Hoffman-Goetz; R Keir
Journal:  Clin Exp Immunol       Date:  1986-01       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.